NCT05365321Unknown1 期
A Phase 1/2, Dose Escalation, and Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral WP1122 in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)
Andrei Carvalho Sposito1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2022年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Difference in the Area Under the Curve (AUC) of Interleukin-6 (IL-6) concentrations
研究概览
简要总结
This is a Phase 1, multi-center, dose escalation study that is followed by a Phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of WP1122 administered q12h ±1 hr PO in adult patients with COVID-19 who require hospitalization with respiratory support.
The Phase 1 component will enroll COVID-19 positive patients who are symptomatic and the Phase 2 component will enroll adults with COVID-19 who require hospitalization for respiratory support and those patients requiring intubation with mechanical ventilation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age at Screening;
- •Confirmed SARS-CoV-2 viral infection by polymerase chain reaction (PCR) within 48 hours prior to first administration;
- •Hospitalized patients who are symptomatic (Phase 1) and require respiratory support (Phase 2);
- •Off antiviral medications for at least 7 days prior to first dose of study drug. (Antiviral agents directed for another ongoing non-SARS-COV-2 infection such as Valtrex (valacyclovir hydrochloride) for herpes simplex virus lesions are allowed;
- •Written informed consent from the patient or legally authorized representative (LAR), if the patient is not able to provide informed consent due to severity of illness;
- •Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening;
- •WCBP must agree to abstain from sex or use an adequate method of contraception* from the time of informed consent through the final in-person evaluations at Day 38 (± 3 days);
- •Males must abstain from sex with WCBP or use an adequate method of contraception* from the time of informed consent through the final in-person evaluations at Day 38 (± 3 days).
排除标准
- •On extracorporeal membrane oxygenation (ECMO);
- •SpO2/FiO2<100 while on respiratory support
- •Use of high dose of >1.0 mcg/kg/min of norepinephrine or need for rescue therapy with vasopressin;
- •Bacterial or fungal infection, except for mild cutaneous infection or sinus infection. Asymptomatic bacteriuria or airway colonization of bacteria is not an exclusion criteria;
- •Pregnant or lactating;
- •Alanine aminotransferase (ALT), Aspartate aminotransaminase (AST) ≥5 times the upper limited of normal (ULN), bilirubin >2 times the ULN (unless previously diagnosed with Gilbert's Syndrome), or International Normalised Ratio (INR) outside of normal limits (unless prolonged due to taking anticoagulants) at Screening
- •Estimated glomerular filtration rate (eGFR) <30 mL/min;
- •Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if they were to participate in the study;
- •Clinically relevant serious co-morbid medical conditions including, but not limited to, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, severe hepatic impairment, active central nervous system (CNS) disease uncontrolled by standard of care, known positive status for human immunodeficiency virus (HIV), active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements;
- •Treatment with any immunosuppressive therapy other than corticosteroids within 30 days prior to Screening;
- •Treatment with another investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer;
- •Prior treatment with the study drug (WP1122);
- •Known hypersensitivity to the inactive ingredients of the study drug (WP1122) or placebo.
- •Participation in another clinical study in less than 1 year (unless justified participation by the principal investigator)
研究组 & 干预措施
WP1122
Experimental
Experimental drug with Concentration 100mg/mL - administered q12h PO for 10 days
干预措施: WP1122 (Drug)
placebo
Placebo Comparator
Placebo Administered q12h PO for 10 days
干预措施: WP1122 (Drug)
结局指标
主要结局
Difference in the Area Under the Curve (AUC) of Interleukin-6 (IL-6) concentrations
时间窗: through the last day of observation (day 10)
Co-primary efficacy endpoints will be utilized in a sequential analysis manner. The first primary efficacy endpoint will be the difference in the AUC of IL-6 concentrations from Baseline (Day 0) through Day 10. For patients who do not have IL-6 values out to Day 10, a last observation carried forward technique will be utilized
次要结局
- COVID-19 negativity(through the last day of observation (day 10))
研究者
Andrei Carvalho Sposito
Principal Investigator and Full Professor of Cardiology
University of Campinas, Brazil
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineChronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT01926587Traws Pharma, Inc.45
招募中
1 期
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsNSCLCGastric CancerEsophageal CancerColorectal CancerNCT03526835Merus B.V.560
招募中
1 期
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaNCT04973605BeOne Medicines246
进行中（未招募）
1 期
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer MetastaticEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaGastric CancerColorectal CancerNCT04868877Merus B.V.194
招募中
1 期
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyAdvanced CancerAdvanced Solid TumorMetastasisMSI-HighMismatch Repair DeficiencyMelanomaPleural MesotheliomaHepatocellular CancerRenal Cell CancerKidney CancerNon Small Cell Lung CancerAnaplastic Lymphoma Kinase Genomic Tumor AberrationsALK Genomic Tumor AberrationsSkin CancerColorectal CancerHepatocellular CarcinomaRenal Cell CarcinomaNSCLCNCT063623697 Hills Pharma, LLC126